2010 Fiscal Year Final Research Report
Development of Cancer Vaccination with Multiple Peptides derived from Novel Cancer-Testis Antigens against esophageal cancer
| Project/Area Number |
20591566
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Yamanashi |
|---|
Principal Investigator |
KONO Koji University of Yamanashi, 大学院・医学工学総合研究部, 准教授 (40283204)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWAGUCHI Yoshihiko 山梨大学, 医学部附属病院, 診療助教 (80402048)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAKAMURA Yusuke 東京大学, 医科学研究所, 教授 (70217909)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 癌ワクチン療法 / 食道癌 / ペプチド抗原 |
|---|
| Research Abstract |
We previously identified three novel HLA-A24-restricted epitope peptides, which were derived from three Cancer-Testis antigens, TTK, URLC10, and KOC1, as targets for cancer vaccination against esophageal squamous cell carcinoma (ESCC). To examine the safety, immunogenicity, and anti-tumor effect of vaccine treatment using a combination of these three peptides, ten HLA-A2402-positive advanced ESCC patients who failed to standard therapy were enrolled in a phase I clinical trial. The cancer vaccination therapy was well-tolerated without any treatment-associated adverse events of grade 3 or 4. The TTK-, LY6K-, and/or IMP-3-specific T-cell immune responses were observed by enzyme-linked immunospot assay in peripheral blood lymphocytes obtained from 9 of the 10 ESCC patients after their vaccination. The vaccination could induce good clinical responses in 50% of the 10 patients. One patient experienced a complete response in hepatic metastasis lasting 7 months, one showed objective responses in all lung metastasis lesions and three patients revealed a stable disease condition for at least 2.5 months. The cancer vaccine therapy using these three peptides demonstrated satisfactory safety and good immunogenicity as well as promising disease control rate, and, therefore, warrants further clinical studies.
|
-
-
[Journal Article] Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody dependent cellular cytotoxicity (ADCC) of EGFR and HER2 over-expressing esophageal cancer cell lines.2011
Author(s)
Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichiro Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono, Aniruddha Choudhury, Rolf Kiessling, Hideki Fujii.
-
Journal Title
Int J Cancer.[Epub ahead of print]
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
